scholarly article | Q13442814 |
P356 | DOI | 10.1016/S2213-8587(19)30080-4 |
P698 | PubMed publication ID | 31003622 |
P2093 | author name string | Josef Coresh | |
Ron T Gansevoort | |||
Lesley A Inker | |||
Hiddo J L Heerspink | |||
P2860 | cites work | Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis | Q35903126 |
Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies | Q91009115 | ||
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials | Q91009119 | ||
P433 | issue | 5 | |
P921 | main subject | chronic renal insufficiency | Q736715 |
P304 | page(s) | 336-337 | |
P577 | publication date | 2019-05-01 | |
P1433 | published in | The Lancet: Diabetes & Endocrinology | Q27725107 |
P1476 | title | Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply | |
P478 | volume | 7 |
Q90066163 | Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial |
Q92435011 | The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists |